Navigation Links
Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries

http://www.reportlinker.com/p0512135/Technology-Transfer-Strategies---A-Guide-to-Maximizing-Returns-Within-the-Pharmaceutical-and-Biopharmaceutical-Industries.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Energy_technology

Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries", which provides insights into global technology transfer strategies landscape.

The report explores the recognized and increasing need for a better understanding between all stakeholders in the biopharmaceutical and pharmaceutical community concerning the efficient transfer of technologies created from early innovative research to the commercialization of new product technologies. The report introduces the concept of technology transfer and the organizational reasons for opting on technology transfer along with the major technologies transferred. It also provides the commercial and scientific advantages along with the analysis of challenges and issues concerning intellectual property management. It also touches upon the use of licensing in technology transfer and reviews the background to licensing. The report also analyzes the strategic options available to the biopharmaceutical and pharmaceutical industry and also predicts the future trends for technology transfer within the industry. In the last chapter, the report also analyzes the key issues concerning the technology transfer regulations and specific legislation relating to the transfer of technology in the emerging countries of Brazil, Russia, India and China.

Scope

The scope of this report includes -

- Detailed overview of technology transfer landscape which includes reasons, types, the process, challenges and critical issues.

- Commercial and scientific advantages and benefits of technology transfer.

- Different intellectual property management strategies in the current technology transfer landscape.

- Adoption, rationale, duration and termination of licensing agreements for technology transfer.

- Future opportunities and challenges with respect to technology transfer in the pharmaceutical industry along with geographic trends covering the US, Europe and Japan.

- Technology transfer legislation and regulation in the emerging markets of Brazil, Russia, India and China which also includes technology transfer process, policies, challenges, trends, funding implications and case studies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Formulate better strategies to enhance your competitive positioning in the technology transfer market by overcoming the major challenges and critical issues

- Improve your product portfolio by identifying the key technologies and its benefits for developing better products

- Negotiate better licensing agreements to in-license or out-license breakthrough technologies that can boost the development of innovative products

- Device a more tailored country strategy through the understanding of key opportunities and challenges in the global technology transfer landscape.

- Develop better market-entry and market expansion strategies for the high growth emerging economies.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Technology Transfer Strategies - Introduction 8

2.1 Introduction 8

2.2 Industry Definition 8

2.3 GBI Research Report Guidance 9

3 Technology Transfer 10

3.1 Technology Transfer, Overview 10

3.2 Reasons for Technology Transfer 11

3.3 Types of Technology Transfer 13

3.3.1 Technology Transfer between Private Companies 13

3.3.2 Technology Transfer between Government or Universities and Private Companies 14

3.4 The Technology Transfer Process 15

3.4.1 National Considerations in the Technology Transfer Process 17

3.4.2 Formal Invention or Technology Disclosure 19

3.4.3 Assessment of Inventions Commercial Potential 20

3.4.4 Invention Protection 20

3.4.5 Marketing the Invention to Existing Companies of Creation of Start-Up Companies 20

3.4.6 Licensing and Other Formal Agreements 21

3.4.7 Commercialization 21

3.4.8 Revenue and Reinvestment 21

3.5 Technology Transfer – Challenges and Critical Issues 22

3.5.1 Cultural Challenges, Change Management Issues and the Determination of Research Goals 22

3.5.2 Challenges Associated with the Technology Transfer Process 22

3.5.3 Technology Transfer License Agreements Structures and Negotiations 23

3.5.4 Protection of Intellectual Property Rights 23

4 Technology Transfer: Commercial and Scientific Advantages and Benefits 24

4.1 Introduction 24

4.2 Enabling the Development and Commercialization of Academic Research Findings 25

4.2.1 Advantages of an Entrepreneurial Atmosphere in an Academic Environment 25

4.2.2 Cultural and Structural Enablers of Commercialization in Academic Institutions 26

4.3 Commercial Considerations: Technology Transfer between Industry and Academia 27

4.3.1 Industry Advantages and Benefits Associated with Technology Transfer with Academia 27

4.3.2 Industry Challenges and Issues Associated with Technology Transfer with Academia 29

4.4 Commercial Considerations in Technology Transfer: Industry and Industry 31

4.4.1 Industry Advantages and Benefits Associated with Technology Transfer between Companies 31

4.4.2 Industry Challenges and Issues with Technology Transfer between Companies 32

4.5 Case Studies 33

4.5.1 Case Study 1: The Emergence of RNA interference (RNAi) as a Major New Business Opportunity 33

4.5.2 Case Study 2: Gaining Competitive Advantage through the Transfer of Technology 34

4.5.3 Case Study 3: Maximizing Return on Investment by Reducing Time to Market and Development Risk 35

5 Intellectual Property Management Strategies 37

5.1 Overview of Intellectual Property Protection and Technology Transfer 37

5.2 Intellectual Property Rights Challenges and Issues 37

5.2.1 Technology Transfer and Issues of Intellectual Property Rights Protection 37

5.2.2 Patenting of Research Tools May Discourage Beneficial Research 39

5.2.3 Publication Delays and Non-Disclosure Agreement (NDA) Requirements May Impair the Openness of the University Research Environment 39

5.3 Intellectual Property Protection Strategies 40

5.3.1 Introduction 40

5.3.2 Identification of the Organization's Commercial Goals and Objectives 40

5.3.3 Identification of the Company's IP Rights and the Competitive IP Landscape 40

5.3.4 Alignment of the Company's IP Rights and Business Objectives 41

5.3.5 Formulation of an IP Strategy 41

5.4 Implementing Intellectual Property Strategies 44

5.4.1 Creation of an IP Management Structure 44

5.4.2 Problems and Solutions with Joint Ownership 45

5.4.3 Securing Intellectual Property Ownership Rights 45

5.4.4 Third Party Rights Management of Intellectual Property 46

5.5 Retain Ownership of Intellectual Property 46

5.5.1 Confidentiality and Non-Disclosure Agreements 46

5.5.2 Negotiating IP Warranties, Disclosure, Indemnities and Disclaimers 47

5.6 Intellectual Property Protection Strategies 47

6 Technology Transfer and Licensing Strategies 49

6.1 Introduction and Background to License Agreements 49

6.1.1 Introduction 49

6.1.2 Types of License Agreements 50

6.1.3 Extent of the Licensing Rights: Commercial and Financial Considerations 51

6.2 The Technology Transfer Office and License Agreements 53

6.3 The Rationale to License Intellectual Property 54

6.3.1 Advantages of Intellectual Property Licensing 54

6.3.2 Disadvantages of Intellectual Property Licensing 54

6.4 In-Licensing 55

6.4.1 Case Study: Warner-Lambert and Pfizer: Lipitor 56

6.5 Out-Licensing 57

6.5.1 Case Study: Out-Licensing by Nektar Therapeutics 57

6.6 Preparing to License a New Technology 58

6.6.1 The Due Diligence Process 58

6.6.2 Reviewing the Intellectual Property Landscape 58

6.6.3 The Role of Confidentiality Agreements 58

6.6.4 Preparation of Memorandum of Understanding or a Letter of Intent 58

6.6.5 Establish Distributor Agreements 59

6.6.6 Assessment of the Technology Value 59

6.7 Negotiating Technology Transfer Licensing Agreements 60

6.7.1 The Preparation Phase 60

6.7.2 The Discussion Phase 60

6.7.3 The Negotiation Process 60

6.8 Duration and Termination of License Agreements 61

6.8.1 Duration of Technology Transfer Licensing Agreements 61

6.8.2 Termination of Technology Transfer Licensing Agreements 61

7 Future Strategies and Opportunities for Technology Transfer 62

7.1 The Future of Pharmaceutical Technology Transfer 62

7.1.1 Private Technology Transfer Sector 63

7.1.2 Public Industry to Academic/Government Sector: Industry – Private Technology Transfer Sector 63

7.2 Technology Transfer by Type 66

7.3 Geographic Trends 67

7.3.1 Technology Transfer in the US 67

7.3.2 Technology Transfer in Europe 71

7.3.3 Technology Transfer in Japan 74

7.4 Licensing and Technology Transfer between the Pharma Industry and Academia 76

7.4.1 Case Study: Kyoto University and Astellas Pharma Inc 76

7.5 The Integrated or Federated Model of Pharmaceutical Research 76

7.5.1 Case Study: Virtual Federated Pharmaceutical Research 77

7.5.2 Case Study: Venture Federated Pharmaceutical Research 78

7.5.3 Benefits of Models 78

7.5.4 Challenges of Models 78

7.6 The Fully Diversified Model of Pharmaceutical Research 79

7.6.1 Case Study: Johnson & Johnson 79

7.6.2 Benefits of Models 79

7.6.3 Challenges of Models 79

8 Technology Transfer Legislation and Regulation in the Emerging Markets 80

8.1 Brazil 80

8.1.1 Technology Transfer Legislation and Regulation 80

8.1.2 Technology Transfer Process 81

8.1.3 Challenges in Technology Transfer 82

8.1.4 Trends in Funding for Universities 82

8.1.5 Implications of Increase in Funding 83

8.1.6 Case Study: GlaxoSmithKline and the Oswald Cruz Foundation (Fiocruz) 83

8.2 Russia 84

8.2.1 Technology Transfer Legislation and Regulation 84

8.2.2 Technology Transfer Process 85

8.2.3 Challenges in Technology Transfer 86

8.2.4 Trends in Funding for Universities 87

8.2.5 Implications of Increase/Decrease in Funding 87

8.2.6 Case Study: Novartis and the City of St. Petersburg 87

8.3 India 88

8.3.1 Technology Transfer Legislation and Regulation 88

8.3.2 Technology Transfer Process 89

8.3.3 Policy for Foreign Technology Agreements 91

8.3.4 Challenges in Technology Transfer 91

8.3.5 Trends in Funding for Universities 91

8.3.6 Implications of Increase/Decrease in Funding 92

8.3.7 Case Study: Biocon, Limited and Amylin Pharmaceuticals, Inc. 92

8.4 China 93

8.4.1 Technology Transfer Legislation and Regulation 93

8.4.2 Technology Transfer Process 95

8.4.3 Policy for Foreign Technology Transfer Agreements 96

8.4.4 Challenges in Technology Transfer 97

8.4.5 Trends in Funding for Universities 98

8.4.6 Implications of Increase in Funding 100

8.4.7 Case Studies of Technology Transfer and its Effects on the Pharmaceutical Industry 100

9 Appendix 101

9.1 Industry Definitions 101

9.2 Abbreviations 102

9.3 Research Methodology 106

9.3.1 Coverage 106

9.3.2 Secondary Research 106

9.3.3 Primary Research 107

9.3.4 Expert Panel Validation 107

9.4 Contact Us 107

9.5 Disclaimer 107

9.6 Sources 108

1.1 List of Tables

Table 1: Technology Transfer, The Principle Provisions of an IP License, 2011 50

Table 2: Technology Transfer, The US, Office of Technology Transfer Activities, 2003–2011 70

Table 3: Technology Transfer, Composition of the sources of funding for R&D at the University of Campinas (Unicamp), 2010 83

1.2 List of Figures

Figure 1: Technology Transfer, Reasons for Technology Transfer, 2011 11

Figure 2: Technology Transfer, Model for Transfer Between Public Research Organizations and the Pharmaceutical Industry, 2011 16

Figure 3: Technology Transfer, Drug Discovery and Development Processes, 2011 17

Figure 4: Technology Transfer, The Cyclical Technology Transfer Process, 2011 19

Figure 5: Technology Transfer, The Role of Innovation in Sustaining Profitability, 2011 28

Figure 6: Technology Transfer, License Support Activities for Product Development Committee, 2011 36

Figure 7: Technology Transfer, Issues, Different Types of Technology Spillover, 2011 38

Figure 8: Technology Transfer, Implementing an IP Strategy, 2011 43

Figure 9: Technology Transfer, Composition of Business Unit Managing IP, 2011 44

Figure 10: Technology Transfer, Intellectual Property Protection Strategies, 2011 48

Figure 11: Technology Transfer, Schematic of Enterprise Hub, 2011 65

Figure 12: Technology Transfer, The US, Schematic of Technology Transfer Process, 2011 68

Figure 13: Technology Transfer, Europe, Typical Process, 2011 71

Figure 14: Technology Transfer, Comparison between Issued Licenses between European and US Universities , 2010 73

Figure 15: Technology Transfer, Japan, Process, 2011 74

Figure 16: Technology Transfer, The Virtual Federated Model of Pharmaceutical Research, 2011 77

Figure 17: Technology Transfer, The Venture Federated Model of Pharmaceutical Research, 2011 77

Figure 18: Technology Transfer, Composition of the sources of funding for R&D at the University of Campinas (Unicamp), 2011 81

Figure 19: Technology Transfer, Schematic of Technology Transfer Process at Indian Institutes of Technology (IITs), 2011 90

Figure 20: Technology Transfer, Technology Transfer Process 95

Figure 21: Technology Transfer, China, Expenditure of R&D and as Percentage of GDP, 2011 98

Figure 22: Technology Transfer, China, Share of Expenditure of R&D by Source, 2011 99

Companies Mentioned

To order this report:

Energy technology Industry: Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries

Energy technology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Analytical Tool - Lymphoma
2. Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope
3. Reportlinker Adds Industrial Biotechnology China News 1104
4. Reportlinker Adds Healthcare Information Technology
5. Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
6. Reportlinker Adds Global Biomaterial Market (2010 - 2015)
7. Reportlinker Adds Genetics Reports Bundle
8. Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
9. Reportlinker Adds Biomarkers: Technologies and Global Markets
10. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
11. Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):